来适可联合非诺贝特治疗混合性高脂血症临床评价.docVIP

来适可联合非诺贝特治疗混合性高脂血症临床评价[摘要] 目的：探讨来适可联合非诺贝特治疗混合性高脂血症临床效果。方法：随机选择2008年11月～2010年4月混合性高脂血症患者70例，治疗前均停用原降脂药物，并服用2周安慰剂作为洗脱期，晨口服非诺贝特100 mg，晚口服来适可10 mg，每晚1次。结果：治疗后TC、LDL-C、TG下降，HDL-C增加，治疗前后比较差异均有统计学意义（均P＜0.05）。治疗效果显效50例，好转12例，无效8例，总有效率为89.33%（67/75）。治疗中有2例出现胃肠道反应，2例出现转氨酶升高，停药后恢复正常，其他肝、肾功能指标均正常，无肌痛发生。结论：联合应用来适可和贝特类的调脂作用较为合理和全面，尤其适用于TC、LDL-C和TG升高伴有HDL-C降低者，其疗效确切，安全有效，副作用小，值得临床进一步探讨和研究。 [关键词] 来适可；非诺贝特；混合性高脂血症 [中图分类号] R589.2 [文献标识码]A [文章编号]1673-7210（2011）03（b）-073-02 Clinical evaluation of Fluvstatin united Fenofibrate in treatment of mixed hyperlipidemia LI Yayun Nantong Tumor Hospital Courtyard South 27 ward, Jiangsu Province, Nantong 226006, China [Abstract] Objective: To explore clinical effects of Fluvstatin united Fenofibrate in treatment of mixed hyperlipidemia. Methods: Seventy patients with mixed hyperlipidemia were randomly selected from November 2008 to April 2010, original lipid-lowering agents were discontinued before treatment, and taking 2 weeks placebo as elution period, morning oral Fenofibrate 100 mg, late oral Fluvstatin 10 mg, every night 1 time. Results: After the treatment, TC, LDL-C and TG declined, HDL-C level increased, compared before and after treatment there were significant difference (all P＜0.05). Healing 50 cases, improvement in 12 cases, invalid in 8 cases, the total effective rate for 89.33% (67/75). During treatment 2 patients suffered from gastrointestinal reaction, 2 cases with transaminase increasing, after discontinuation normal liver, renal function and other reactive index were all normal, no myalgia happening. Conclusion: Combined application of Fluvstatin and Fibrates adjustment function is more reasonable and comprehensive, particularly suitable for patients with TC, LDL-C and TG rising and HDL-C reducing, with definite effect, safe and effective, side effect is small, and is worth clinical further discussion and study. [Key words] Fluvstatin; Fenofibrate; Mixed hyperlipidemia 高脂蛋白血症可加速动脉粥样硬化的发展，他汀类药物通过降低血胆固醇水平而降